Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Inder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known for form 1449A/B/PTO Application Number 09/913,419-Conf. #9005 INFORMATION DISCLOSURE Filing Date August 8, 2001 Jamie Rossjohn STATEMENT BY APPLICANT First Named Inventor N/A 1646 Art Unit (Use as many sheets as necessary) Examiner Name P. M. Mertz 03991/000J678-US0 Sheet 1 of 1 Attorney Docket Number

U.S. PATENT DOCUMENTS						
Examiner Cite Initials* No.1 Nu		Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	

FOREIGN PATENT DOCUMENTS							
Examiner tnitials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Cotumns, Lines, Where Relevant Passages or Relevant Figures Appear		
		Country Code ³ -Number ⁴ -Kind Code ⁸ (if known)				⊤°	
PM	ВА	WO-97/07215-A	02-27-1997	Medvet Science Pty., Ltd.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov.or/ or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as Indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	book, city T ²				
pm 1	CA	Sun, Q. et al., "A Monoclonal Antibody (MOAB) to the Human IL-3, GM-CSF and IL-5 Receptor Common Beta-Chain (BETAC) Neutralises the Binding and Function of All Three Ligands:m Blood, W.B. Saunders, Philadephia, VA, US, Vol. 88, No. 10 SUP01PT01/2, November 15, 1996, page 545A, Abstract.					
	СВ	Sun, Q., et al., "Simultaneous antagonism of interleukin-5, granulocyte-macrophage colony-stimulating factor, and interleukin-3 stimulation of human eosinophils by targetting the common cytokine binding site of their receptors", Blld, W.B. Saunders Company, Vol. 94, No. 6, September 15, 1999, Abstract, page 1944.					
	CC	Woodcock, J.M. et al., "The human granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor exists as a preformed receptor complex that can be activated by GM-CSF, Interleukin-3, or interleukin-5:, Blood, W.B. Saunders, Vol. 90, No. 8, October 15, 1997, Page 3006. Abstract.					

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature	Prima	Ment	Date Considered	4	26	05
		3			1	

^{&#}x27;Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.